Sector Expert: Jason McCarthy

Maxim Group

Image: Jason McCarthy

Jason McCarthy, Ph.D., is an equity research analyst covering the biotechnology industry at Maxim Group. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in biomedical sciences from the Albert Einstein College of Medicine. McCarthy also holds master's degrees in both biomedical research (Albert Einstein College of Medicine) and molecular biology (Adelphi University), as well as a bachelor's degree in biochemistry from Stony Brook University. He closely follows gene therapy, CAR-T and the cancer immunology spaces, as well as many traditional biotechnology companies.



Recent Interviews

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease (5/2/18)
PastelStemCells580

In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors (4/25/18)
PastelStemCells580

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront.

Stellar Biotechnologies (SBOT:NASDAQ) Could Rise with KLH Vaccine Trial Success (3/1/17)
Beaker and News Update

Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Maxim currently has a price target of $4 on Stellar and the stock currently trades at around $1.65.

Recent Quotes

"INO's vaccine showed 100% protection against the Lassa fever virus."

— Jason McCarthy, Maxim Group (10/24/17)
more >

"INO continues to advance multiple early-stage studies forward which should provide incremental catalysts as data emerges."

— Jason McCarthy, Maxim Group (10/16/17)
more >

"INO announced positive (Phase 1b) data for INO-5150."

— Jason McCarthy, Maxim Group (9/12/17)
more >

"INO is a pivotal company and multiple pipeline programs continue to advance."

— Jason McCarthy, Maxim Group (8/9/17)
more >

"While INO has continued to advance multiple earlier-stage DNA-based immunotherapies forward, providing incremental catalysts for the stock, our focus has remained on the start of the P3 program for VGX-3100 in high-grade cervical dysplasia."

— Jason McCarthy, Maxim Group (6/8/17)
more >

"INO announced a collaboration with Roche to evaluate their DNA-based immunotherapies in advanced bladder cancer."

— Jason McCarthy, Maxim Group (6/1/17)
more >

"INO's immune responses demonstrated by PENNVAX-GP are among the highest responses shown for an HIV vaccine."

— Jason McCarthy, Maxim Group (5/24/17)
more >

"INO continues to advance multiple immunotherapy studies forward, which should provide incremental catalysts for the stock as data emerges."

— Jason McCarthy, Maxim Group (5/11/17)
more >

more comments

"IMV announced dosing of the first patient in the P1b/2 study in HPV-related cancers has been dosed with DPXE7."

— Jason McCarthy, Maxim Group (4/19/17)
more >

"INO's VGX-3100 study should start in 1H17, multiple catalysts ahead in other programs."

— Jason McCarthy, Maxim Group (3/16/17)
more >

"No one else can supply KLH at the quality and the quantity that SBOT can."

The Life Sciences Report Interview with Jason McCarthy (3/1/17)
more >

"End of phase II meetings with both the FDA and EMA have given INO a path forward for a pivotal study of VGX-3100."

— Jason McCarthy, Maxim Group (2/23/17)
more >

— Jason McCarthy, Maxim Group (12/16/16)
more >

— Jason McCarthy, Maxim Group (12/2/16)
more >

"Our focus continues to be on INO's VGX-3100 and the start of the pivotal program as the next major event, now potentially in 2017."

— Jason McCarthy, Maxim Group (10/24/16)
more >

fewer comments


Due to permission requirements, not all quotes are shown.